文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.

作者信息

Rousseau Benoit, Foote Michael B, Maron Steven B, Diplas Bill H, Lu Steve, Argilés Guillem, Cercek Andrea, Diaz Luis A

机构信息

Memorial Sloan Kettering Cancer Center, New York, NY.

Johns Hopkins Medical Institutes, Baltimore, MD.

出版信息

N Engl J Med. 2021 Mar 25;384(12):1168-1170. doi: 10.1056/NEJMc2031965.

DOI:10.1056/NEJMc2031965
PMID:33761214
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8403269/
Abstract
摘要

相似文献

[1]
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors.

N Engl J Med. 2021-3-25

[2]
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

N Engl J Med. 2015-6-25

[3]
Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

Clin Colorectal Cancer. 2019-12

[4]
Mismatch repair deficiency predicts benefit of anti-PD-1 therapy.

Lancet Oncol. 2015-7

[5]
Engineering Tumor Hypersusceptibility to Checkpoint Immunotherapy.

Trends Cancer. 2017-10

[6]
Hypermutated Tumors and Immune Checkpoint Inhibition.

Drugs. 2018-2

[7]
Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

N Engl J Med. 2020-12-3

[8]
Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?

J Hematol Oncol. 2015-11-5

[9]
Immunotherapy in colorectal cancer with mismatch repair deficiency.

Clin Adv Hematol Oncol. 2019-5

[10]
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Science. 2017-7-28

引用本文的文献

[1]
Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.

Cancers (Basel). 2025-8-16

[2]
Blood immunomap for prediction of responses to anti-PD-1 immunotherapy in metastatic non-small cell lung cancer.

iScience. 2025-6-2

[3]
Therapeutic targeting of mismatch repair-deficient cancers.

Nat Rev Clin Oncol. 2025-7-10

[4]
Role of tumor mutational burden in patients with urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis.

Front Immunol. 2025-5-26

[5]
Optimising Cancer Medicine in Clinical Practices: Are Neoadjuvant and Adjuvant Immunotherapies Affordable for Cancer Patients in Low- and Middle-Income Countries?

Cancers (Basel). 2025-5-21

[6]
[Chemotherapy, targeted therapy and immunotherapy of metastatic colorectal cancer : What is new?].

Radiologie (Heidelb). 2025-4-24

[7]
Enhancing immunotherapy with tumour-responsive nanomaterials.

Nat Rev Clin Oncol. 2025-4

[8]
Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer.

bioRxiv. 2025-2-17

[9]
Current and future perspectives in the management and treatment of colorectal cancer.

World J Clin Oncol. 2025-2-24

[10]
Anti-PD1 based precision induction therapy in unresectable stage III non-small cell lung cancer: a phase II umbrella clinical trial.

Nat Commun. 2025-2-24

本文引用的文献

[1]
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

Lancet Oncol. 2020-9-10

[2]
Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

Nat Genet. 2019-1-14

[3]
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Science. 2017-7-28

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索